April 2020 Medtech News + Insights Special COVID-19 Issue
April 2, 2020
StarFish Medical April 2020 Medtech News + Insights is now online. In this special COVID-19 Issue: Supply Chain Tips for COVID-19 COVID-19 Point of Care...
August 15, 2017
Medical Device Developer StarFish Medical Engaged
MELBOURNE — 15 August 2017 — Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Service Agreement with StarFish Medical (“StarFish”), Canada’s largest medical device design, development and contract manufacturing company, to assist in the design and development of the MagSense instrument platform for clinical applications.
StarFish Medical is an ISO 13485 certified product engineering firm with offices in Victoria, British Columbia, and Toronto, Ontario, with extensive experience in the design and manufacturing of medical devices. The agreement provides Imagion an engineering organisation able to translate the company’s current prototype systems into a product that can meet regulatory requirements for use in first-in-human testing.
The agreement with StarFish initiates the first phase in the development of the industrial design of Imagion’s MagSense instrument. Working with StarFish, the Company will establish the clinical instrument design specifications and StarFish will provide Imagion with a mockup of the instrument before committing to the building of prototypes for human studies and market development.
“Building a clinical prototype instrument that can be used in human studies, is an important step for us,” said Robert Proulx, CEO of Imagion. “We chose StarFish because of their depth in medical device engineering and experience in magnetic imaging systems. I am convinced they can help us turn our technology into a commercial product. In parallel with this design project, we continue to work towards cGMP manufacturing of our formulated nanoparticles, followed by stability and toxicity studies. The team at Imagion remains focused on pursuing these goals expeditiously and cost effectively to get to first-in-human testing.”
“We are thrilled to be working with one of the true innovators in cancer detection”, said Scott Phillips, Founder and CEO of StarFish Medical. “Imagion’s technology is very unique and we believe it represents a big step forward in diagnostics.
About Imagion Biosystems
Imagion Biosystems is at the crossroads of biotechnology and nanotechnology. Its novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. With MagSenseTM technology, the company has the potential to optimise patient care and reduce mortality rates across various cancer indications. Based in Albuquerque, New Mexico, Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
About StarFish Medical:
StarFish Medical provides award-winning design, development, and flexible manufacturing outsourcing services —100% dedicated to the medical device and life science marketplace. StarFish partners with innovative companies to create and manufacture breakthrough products for a full range of medical specialty areas including: Cardiovascular, Digital Health, IVD, Ophthalmology, Optics, and Ultrasound. StarFish expertise includes electronics, mechanical, human factors and software systems engineering.
For further information please contact:
U.S. Media Contact: Australian Media & Investor Relations:
Matthew Wygant Matt Wright, NWR Communications